Ethical issues in human genomics research in developing countries by de Vries, Jantina et al.
DEBATE Open Access
Ethical issues in human genomics research in
developing countries
Jantina de Vries
1,2*, Susan J Bull
1,2, Ogobara Doumbo
3, Muntaser Ibrahim
4, Odile Mercereau-Puijalon
5,
Dominic Kwiatkowski
2,6 and Michael Parker
1
Abstract
Background: Genome-wide association studies (GWAS) provide a powerful means of identifying genetic variants
that play a role in common diseases. Such studies present important ethical challenges. An increasing number of
GWAS is taking place in lower income countries and there is a pressing need to identify the particular ethical
challenges arising in such contexts. In this paper, we draw upon the experiences of the MalariaGEN Consortium to
identify specific ethical issues raised by such research in Africa, Asia and Oceania.
Discussion: We explore ethical issues in three key areas: protecting the interests of research participants, regulation
of international collaborative genomics research and protecting the interests of scientists in low income countries.
With regard to participants, important challenges are raised about community consultation and consent. Genomics
research raises ethical and governance issues about sample export and ownership, about the use of archived
samples and about the complexity of reviewing such large international projects. In the context of protecting the
interests of researchers in low income countries, we discuss aspects of data sharing and capacity building that
need to be considered for sustainable and mutually beneficial collaborations.
Summary: Many ethical issues are raised when genomics research is conducted on populations that are
characterised by lower average income and literacy levels, such as the populations included in MalariaGEN. It is
important that such issues are appropriately addressed in such research. Our experience suggests that the ethical
issues in genomics research can best be identified, analysed and addressed where ethics is embedded in the
design and implementation of such research projects.
Background
Recent years have seen an explosion of scientific interest
in the use of human genomic variation to study com-
mon complex diseases. The hypothesis is that human
genetic diversity can be used as a tool to study the cau-
sal mechanisms of disease. Examples include Genome-
Wide Association studies (GWAS) and, more recently,
projects that make use of next-generation sequencing.
Over the past 5 years, GWAS have proven very valuable
in identifying regions of the genome that affect resis-
tance or susceptibility to a wide range of common dis-
eases, although the method provides simply a starting
point, and a range of other approaches will be required
in future to fully characterise and understand the
complex genetic determinants of human health and dis-
ease. To date, whilst many such studies have taken place
focussing on a wide range of conditions, hardly any of
these have been applied to diseases that primarily affect
people in lower income countries [1,2].
There are good ethical reasons for encouraging medi-
cal research on diseases affecting populations with lower
average income and literacy levels. Substantial global
inequalities exist in health measures such as mortality,
quality of life and disease incidence. These persist
despite increasing levels of overall wealth [3,4]. Even
today, only a small proportion of medical research
focuses on the problems primarily affecting the world’s
poorest people [5]. Applying the methods of genomics
research to these diseases is one way to address this
imbalance.
Genomics research raises a number of ethical chal-
lenges wherever it is carried out [6,7]. Some of the
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any medium, provided the original work is properly cited.issues identified in the literature to date include consent
[8,9], privacy [10-12] and the collection, storage and
release of genomic data [13,14]. Despite the existence of
a substantial and developing literature on the ethical
issues arising in genomic studies, this literature has as
yet not adequately addressed the specific ethical chal-
lenges presented by genomics research which takes
place in the context of collaborative global health part-
nerships between high and low income countries. This
paper aims to begin to address this gap by reporting on
the ethical challenges that have been identified in the
development of the Malaria Genomic Epidemiology Net-
work (MalariaGEN), a partnership of malaria researchers
in over 20 countries supported by the Grand Challenges
in Global Health Initiative [15].
Malaria is a so-called complex disease, involving an
intricate immunological pathway and dynamic relation-
ships between the human, the mosquito and the malaria
parasite [16-18]. Malaria is one of the leading causes of
infant mortality in tropical countries, causing the deaths
of nearly 1 million children under five in 2006 [19], as
well as debilitating illness in a quarter of a billion people
worldwide [19,20]. By combining large-scale epidemiolo-
gical studies with state-of-the-art genomic technology,
GWA studies hope to use human genetic diversity as a
tool to study the causal mechanisms of disease [17].
MalariaGEN research is conducted in several countries
in Africa, Asia and Oceania. An overview of study sites
can be found on the project website, http://www.
malariagen.net. Whereas our experience is relevant to
populations in these countries, we believe that what
essentially distinguishes the MalariaGEN research from
other genomic research conducted in wealthier parts
of the world, is lower average income and literacy
levels. Our findings may therefore be equally relevant
to genomic research conducted on poorer populations
in other parts of the world.
Discussion: Ethical Issues in Human Genomics
Research in Lower Income Countries
i. Protecting the interests of research participants
Whilst genomics research presents important ethical
challenges in the recruitment of participants regardless
of where it is conducted, prospective participants in
l o w e ri n c o m ec o u n t r i e sa r em o r el i k e l yt ob ep o o ra n d
to have limited access to healthcare, education and
other resources. This means that the carrying out of
research in these setting invariably presents challenges
of a different order to those in higher income countries.
In this section, we explore the particular challenges pre-
sented by genomic research for community participation
and the obtaining of valid consent.
Community engagement
Driven both by recognition of the need for locally rele-
vant health research in lower income countries, and by
awareness of the potential for exploitation in contexts of
vulnerability and inequality [21], collaborative partner-
ship and social value have been proposed as benchmarks
against which the ethics of research in lower income
countries should be measured [22,23]. The empirical lit-
erature that exists on community partnership tends to
show that the achievement of these benchmarks may
only really be possible in the context of effective and
sustained community engagement and accountability
[24-26]. Community engagement strategies therefore are
increasingly seen as a key element of ethical best prac-
tice in research. Despite this growing emphasis on the
importance of community engagement however, there is
still relatively little published experience or evaluation of
engagement in practice. There is certainly a need for
more research in this area, and for the sharing of mod-
els of good practice.
Notwithstanding its importance, the actual achieve-
ment of successful and appropriate community engage-
ment presents a number of practical and ethical
challenges. Some of these relate to the question of how
the relevant community is to be identified and repre-
sented [24,27]. Others concern the identification and
establishment of procedures, principles and mechanisms
of engagement that are fair, inclusive, accountable and
appropriate to the research setting [28,29].
In the course of its development, a number of issues
specific to international collaborations were identified by
the MalariaGEN Network. One of these concerned the
relationship between the need to establish shared good
community engagement practices across the network on
the one hand, and the need for sensitivity to local varia-
tion on the other. MalariaGEN studies were conducted
across a wide range of settings, spanning from referral
hospitals in urban areas to traditional rural villages.
Each of these settings involved very different kinds of
‘communities’, all with their own decision-making
strategies.
In the context of such diversity, identifying common
ground where researchers can share experiences and
insights is inevitably challenging. The extent to which
‘best practice’ can be shared and translated across such
contexts will depend on a wide range of factors particu-
lar to the nature of the research and its location(s). In
practice, MalariaGEN researchers across the network
engaged in some form of community engagement, but
the majority of such initiatives were developed ad hoc
by researchers in the absence of agreed-upon guidelines
for best practice or even a toolkit for community
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presents important challenges for researchers in mean-
ingfully engaging with research communities.
Another practical challenge in the context of commu-
nity participation in genomics research concerns how to
explain to communities what the study involves in ways
that are accessible and make understanding and engage-
ment possible. Some suggestions have been made about
how to explain key terms of genomic studies [30], but
the extent to which such abstractions effectively explain
the risks and benefits involved remains yet to be seen.
Particularly challenging is the fact that many of the
potential harms and benefits of genomics research relate
to populations rather than to individuals [31]. Whether
this is an important feature of genomic studies for com-
munities and participants, and how it could best be
explained and discussed, requires further investigation.
Within the context of MalariaGEN, we did not resolve
ways of addressing these challenges. The complexity of
community engagement exercises is widely acknowl-
edged [24,27,32], and there may not be a one-size-fits-
all solution. But in our experience, these are important
challenges in the context of international collaborative
genomics research, and are going to require careful
attention in the establishment and maintenance of suc-
cessful research networks. Scientific researchers cannot
be expected to face these challenges alone, and con-
structive collaboration is needed with others knowledge-
able in local community structures and processes and
ethics, preferably as an integral part of the research
process.
Valid consent
Valid consent for research participation must be ade-
quately informed and understood, voluntary, and given
by someone who is competent to do so [33]. It also
requires the processes through which consent is
obtained to be locally appropriate [34]. Designing and
implementing consent processes in the context of colla-
borative genomics research on populations characterised
by lower average income and literacy levels presents
many challenges. Some of the difficulties relating to the
development and implementation of consent processes
in lower income countries have been discussed in the
literature [35-38]. However, little of this addresses the
particular issues presented by the novel field of geno-
mics research.
A critical challenge to achieving valid consent in lower
income countries arises in relation to providing appro-
priate information to participants in a comprehensible
manner [39]. In genomics, challenges are presented by
the need to explain concepts such as ‘genetics’, ‘geno-
mics’, ‘data release’, and the reasons underlying the need
to collect large numbers of healthy population controls
[28]. It may be possible to link these concepts to local
knowledge of genetics, for instance that particular facial
traits are often inherited within families [40]. But
although it may be possible to explain some aspects of
genomics research in ways that are not entirely alien to
research participants, ensuring that participants give
valid consent for genomic studies remains a significant
challenge.
There are other challenges to obtaining valid consent
for genomics research. Information produced by geno-
mic research has, for example, the potential to be infor-
mative about people other than the research participant.
There has been much discussion about the importance
of privacy protection for individual research participants
in genomic studies [41-43]. Where personal identifiers
are removed from genomic datasets there may arguably
be limited risk of participant identification. Yet even
where this is the case, there remains a possibility that
unwanted information about populations, communities
or families will be revealed. At the population level,
GWA studies have for example the potential to reveal
that a stigmatising condition is more likely to occur in
one population than another [8]. In that sense, it raises
the possibility that genomic data could be used in ways
that would have adverse effects for the populations
involved, possibly through generating research results
that could be used to stigmatise groups based on their
genetic make-up [44,45]. There may be a need to take
this kind of issue seriously when designing consent pro-
cesses for genomics.
The MalariaGEN Network has sought to address some
of these challenges through the collaborative develop-
ment of an informed consent template and guidelines
for informed consent http://www.malariagen.net/home/
ethics/consentpolicies.php. These were developed by
and for MalariaGEN researchers and in consultation
with some ethics committee members. In addition, the
MalariaGEN ethics team (JdV, SB and MP) discussed
the consent procedures, challenges and best practice
with researchers and fieldworkers at several research
sites. Particular challenges with regard to consent were
how to collect consent in emergency situations, and
how to explain the rationale for collecting samples from
healthy children. A key strategy of genomic studies, like
the MalariaGEN study, is comparing genomic data
between children that are ill with malaria (the cases)
and healthy children (the controls). The collection of
both types of samples raised issues with regard to con-
sent. Namely, children presenting at the hospital were
often severely ill and required immediate medical assis-
tance. Timing of consent in this emergency setting pre-
sented a real challenge in these cases. On the other
hand, the genomic study requires the collection of blood
samples from healthy children as well. Explaining the
reason for collecting blood samples from healthy
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MalariaGEN study. The complexities of resolving these
issues were such that further empirical research was
conducted at two MalariaGEN research sites, with the
aim of investigating how best to obtain consent for
genomic studies in low income countries. Papers report-
ing on the results of these studies are forthcoming.
ii. Regulating human genomics research
Where genomics research focuses on diseases affecting
populations with lower average income and literacy
levels, it tends to take place in collaborations between
researchers from higher and lower income countries.
For example, whereas the infrastructure for genotyping
and whole genome analysis is usually based in higher
income countries, the patients affected by the diseases
are based in lower income countries. This distribution
of research resources raises important issues about the
use of archived samples, sample ownership and ethics
review by multiple committees.
Sample export and ownership
Because GWA studies require access to sophisticated
laboratories and large-scale genotyping facilities with
attendant statistical expertise, most of which are cur-
rently only available in a few countries in the world,
samples collected for GWA studies are often exported
for processing, quality control and genotyping. The
export of samples from lower income countries is
increasingly seen to present important ethical issues
both by researchers and by research ethics committees
[46]. Many of these arise from concerns from research-
ers and ethics committees in the samples’ country of
origin that once samples have been exported, their con-
trol over subsequent use will be limited [47,48]. At least
part of the concern is that whilst samples were often
collected for a particular purpose on the basis of a rela-
tionship of trust between researcher and research parti-
cipant, this relationship of trust may become diluted
when samples from different studies are used in
research abroad by scientists who have never met the
participants nor are familiar with the samples’ country
of origin. Upshur and colleagues argue that important
contextual understandings such as the cultural value of
tissues and samples may get lost if researchers who have
no knowledge of the culture prevalent in the place in
which samples were collected, perform the majority of
work and analysis on the samples [47]. The absence of
agreed-upon policies for export, sample handling and
destruction [48,49], as well as the fear that samples may
take on monetary value in international research [50],
can aggravate such concerns.
A key challenge for genomics research conducted on
populations with lower average income and literacy
levels is how conditions can be created under which it
is possible for researchers and research ethics commit-
tees to feel confident that samples and data will be used
appropriately, and that the decision-making process for
their use is sufficiently transparent. In MalariaGEN, the
export of samples was found to be a particular stum-
bling block for ethics committees. The committees
required detailed information on the need to export
samples, as well as descriptions of the exact sample
handling. Specific Material Transfer Agreements
(MTAs, Case 1) describing in detail the nature of the
work to be carried out in foreign laboratories, as well as
procedures for sample return or destruction at the end
of the project, were instrumental in addressing some of
these concerns. In some instances, submission of signed
MTAs was a requirement for ethics approval.
| Case 1 | Material Transfer Agreements
A Material Transfer Agreement is a contract between
two parties involved in a research project that specifies
exactly the nature of work that is to be done on mate-
rials given by the one party to the other. It typically
consists of specifications of the following elements:
￿ the materials to be transferred;
￿ the exact work to be done on the materials;
￿ the conditions of storage of the materials, including
for instance details on building access and security;
￿ the people that are to work with the samples, typi-
cally the heads of research groups and all the mem-
bers of their group;
￿ the duration of the collaboration;
￿ an agreement about data sharing and collaboration
in analysis;
￿ procedures for agreeing on any other work that is
not covered in the current MTA.
MTAs are an important means of protecting the
interests of the researchers collecting and supplying
samples. In MalariaGEN, they were instrumental in
addressing the concerns of ethics committees regard-
ing ownership, long-term storage and sample re-use.
It is important to remember, however, that whereas
MTAs can play a significant role in organising the legal
responsibilities in the research process, they cannot
accommodate all the above challenges. In particular,
issues of perceived symbolic (non-legal) ownership over
DNA, and concerns about whether a populations’
genetic material relates to its identity, have long played
an important role in genetic and genomics research
[51-53]. In addition, where genomics research takes
place in the context of resource inequalities between
research partners, the concentration of samples and
resources in particular partner sites raises questions
about fairness, ethical oversight, benefit sharing, and
long-term development of capacity at all research sites.
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made to address these more exacting challenges, in
addition to MTAs and research contracts. First, the net-
work developed a capacity building scheme in which
young researchers from all partner sites were trained in
the analysis of genomic data (see section Capacity Build-
ing). Second, the network recognised the need to enable
all contributing researchers to analyse their own data
before it was made publicly available and incorporated
this into the MalariaGEN Data Release Policy http://
www.malariagen.net/home/downloads/16.pdf. Third, the
network sought to develop software that allows the
remote analysis of genomic data - meaning that Malaria-
GEN researchers anywhere in the world could analyse
data without the need to invest in expensive in-house
infrastructure for data analysis and storage. Funding has
also been obtained to fund a PhD studentship to explore
the issues relating to the collection, storage and export
of biological samples and to work towards the develop-
ment of recommendations on good practice.
Archived samples
Successful GWA studies require the collection of very
large numbers of samples and well-characterised pheno-
types. This is labour-intensive and time consuming,
even in well-resourced health systems. Moreover, the
conditions and lack of infrastructure for treatment and
research in lower income countries are often not condu-
cive to the rapid collection of the very large numbers of
samples required for genomic studies. Significant
improvements in malaria treatment and prevention
[54,55] also mean that fewer samples are available for
research on that disease. Taken together, these factors
mean that GWA studies such as MalariaGEN need to
rely heavily on the use of archived samples.
The use of archived samples raises a number of
important ethical challenges. The relatively recent devel-
opment of genomics means that it is unlikely that con-
sent to studies conducted a few years earlier would have
included it. Questions therefore arise about how deci-
sions about the re-use of such samples should be made
and who should be making them. One issue concerns
the legitimacy of ethics committees to represent the
views of research participants and to decide on re-use
on their behalf [48,49,56]. Further issues arise about
whether there are cases in which re-consent should be
required or whether there are forms of research
for which new samples should be collected altogether.
A balance may need to be struck between the ethical
implications of collecting many thousands of new sam-
ples against the ethics of using archived samples with
less than ideal consent.
For MalariaGEN, almost all contributed samples were
originally collected for research on malaria, but only a
subset was collected with consent for genomic or
genetic studies. All ethics committees reviewing the
MalariaGEN studies approved the inclusion of archived
samples in the prospective genomic study. Only in one
site did researchers decide to re-consent participants
whose samples were collected many years ago, but this
was mainly because the research design of the particular
sub-study required taking additional samples.
Ethics review
International collaborative research projects need to
obtain ethics approval from a multitude of committees
from around the world. This can be a daunting task,
especially where committees express different or con-
flicting points of view or place additional requirements
on researchers [57], such as changes to a consent form
that has already been approved by another ethics
committee.
The review of genomic studies is challenging: the
science is difficult to comprehend [58], the studies are
hypothesis-generating rather than hypothesis-testing, use
very large sample numbers [59,60], and generate very
large amounts of data that can be analysed many times
for different purposes. In addition, genomic studies take
place in a context where data sharing is the norm [61].
This raises ethical challenges that may not be familiar to
members of ethics committees. Ethics committees
reviewing research in this area may not have had the
training or experience to enable them to identify and
analyse the key ethical issues - a well-recognised pro-
blem also in other research fields [62-64]. In addition,
many of the key ethical challenges of GWA studies have
only been identified fairly recently. Pertinent issues like
consent and privacy remain the topic of debate [43],
and consensus about the best approach to accommodate
these challenges in research has not been reached.
It is therefore hardly surprising that obtaining ethics
approval for the various MalariaGEN studies was a sig-
nificant challenge. Over twenty ethics committees in
sixteen countries reviewed and approved the study, with
review taking up to a year to complete at some partner
sites (see Case 2). For many of these committees, the
MalariaGEN study was one of the first genomic studies
to be reviewed.
The MalariaGEN study was approved by all ethics
committees, although in some cases the approval pro-
cess consisted of multiple rounds of correspondence to
clarify study design and rationale. Overall, there was
considerable homogeneity in the concerns raised by
committees in various countries. The main points raised
concerned: how to ensure that participants give valid
(informed) consent; justifications for the export of sam-
ples and specification of the procedures for sample
return or destruction at the end of the project; ensuring
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butions and capacity development; ensuring that geno-
mic data will not be used to harm populations or
countries; and ways of assigning benefits to the country
or community that donated the samples.
A particular challenge relates to fast increases in the
number of genetic variants that can be reasonably geno-
typed for a project like MalariaGEN. Genomics is a fast-
moving field and new technological opportunities are
developed monthly. These ought to be exploited to
maximise the power of genomic studies; yet they may
mean that the ethics approval is outdated.
MalariaGEN adopted two ways of approaching the
challenge of obtaining ethics review. First, it held a
number of ethics workshops to which members of some
of the ethics committees were also invited. In this way,
MalariaGEN received some very important feedback
about what were perceived to be the key ethical chal-
lenges by ethics committee members, which could in
turn be integrated into project policies and proposals.
Second, when the Network was seeking to address parti-
cular issues, such as data sharing, it sought to establish
working relationships with ethics committees to receive
feedback on proposed policies. This enriched the Net-
work’s thinking about particular ethical challenges relat-
ing to the MalariaGEN studies.
| Case 2 | Ethics Review and the
Malariagen Ethics Team
The MalariaGEN Network has adopted an integra-
tive approach to ethics, with a team of ethicists work-
ing alongside researchers to identify and address
ethical challenges relevant to the scientific project.
One way in which this approach has benefitted the
Network is in providing assistance during ethics
review. In consultation with project members, the
MalariaGEN ethics team developed template infor-
mation about the project, including information
about the methodology, preliminary data sharing
principles and ethical issues. This information was
subsequently used by many local researchers in their
MalariaGEN ethics application.
The MalariaGEN ethics team also provided assis-
tance in interpreting and answering any queries that
ethics committees raised in the review process, or in
liaising between project management and ethics com-
mittees in addressing local concerns. Lastly, the ethics
team provided a bridge between ethics committees
and researchers in addressing pertinent ethical chal-
lenges at later stages in the project. Most impor-
tantly, it facilitated a discussion of ethical
considerations important in the context of data
sharing.
iii. Protecting the interests of scientists
in the developing world
A fundamental principle underlying many genomics
research projects is that data should be shared with
third party researchers for secondary analysis. Whereas
this principle may be ethically laudable in promoting
the utility of data, it is also based on an assumption that
all researchers have equal access to the data, and com-
parable facilities and abilities to analyse it. This assump-
tion does not hold for all researchers, and especially not
for those based in low-income countries. A specific
focus on equality and fairness may be necessary to pro-
tect the interests of those researchers.
Data sharing and data release
There are strong scientific and ethical arguments for
sharing genomic data as the full scientific value of a
GWA study may not be realised unless it is analysed by
different methods and combined with other datasets.
Despite the ethical importance of promoting the avail-
ability of genomic data to the scientific community [65],
moves towards open access have also generated a signif-
icant literature concerning the compatibility of open
access with important ethical principles and values [61].
The range of ethical issues identified is extensive. It
includes concerns about: privacy and whether anonymity
can be guaranteed [10]; data security [11]; the implica-
tions of collecting and storing vast amounts of data and
its uncertain future use; the implications of data release
for populations and for family members of participants
[7]; the need to strike a proper balance between
research and protection [65]; the development of appro-
priate governance mechanisms [31]; the implications for
trust, consent and autonomy [45,66]; commercialisation;
and the ethical importance of the sustainability of
databases.
While MalariaGEN was founded with open access in
mind [13] it was clear that the development of an effec-
tive, appropriate approach to GWA data release
required widespread consultation across the network
and with external stakeholders. After extensive discus-
sion within the Network, and consultation with parties
outside it, it was concluded that it would be inappropri-
ate to provide unrestricted public access to GWA data
on individuals accompanied by specific phenotypic data.
Following consultation, it was agreed that access to
MalariaGEN datasets would be mediated via an inde-
pendent data-access committee and that researchers
would be granted access to genotyping data and to a
limited amount of clinical and demographic data only
after signing a legally-binding data-access agreement
which placed restrictions on the acceptable uses
to which MalariaGEN data can be put [14]. The princi-
ples set out in the MalariaGEN Data Access Policy
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researchers agreed should be respected by any third
party using the genomic data. Particularly important fac-
tors in deciding to regulate data access were the poten-
tial for genomic data associated with ethnicity to lead to
ethnic stigmatisation and the importance of ensuring
that future data uses are compliant with the purposes
for which the samples were collected.
Another key reason for adopting a managed approach
to data release was the view that an ethical data release
policy must also be combined with adequate protections
for researchers in lower income countries. Where data
is open access, training and capacity building activities
are necessary to ensure that researchers in the lower
income countries have a fair chance to publish their
analyses of the study [14].
Capacity building
A significant challenge for sustainable GWA studies in
lower income countries concerns the development of
research capacity across participating research sites.
Where researchers are engaged in the collection of large
numbers of samples, it is vital that they are also in a
position to analyse research results, and to use their
contribution for career development. Capacity building
would also allow scientists to enlarge their analyses to
additional, locally-held phenotypes or to build on key
genomic findings to develop further research projects.
Such projects could aim at understanding the biological
mechanisms relating to the genetic effect, or undertak-
ing additional genetic studies. For GWA studies, capa-
city building is also imperative as benefit sharing as the
main outcomes of the research are likely to be expertise
and knowledge, rather than treatments.
After genotyping or sequencing is completed, GWA
studies are strongly reliant on bioinformatics and com-
putational technology and infrastructure, but not all
these need to be present at the site where analysis is
conducted. Especially when data is accessed from a dis-
tance, genomic analysis is relatively affordable. Thus,
genomic methodology may offer excellent opportunities
for real and sustainable involvement from researchers in
lower income countries (See Case 3). A key bottleneck,
however, is the ability to work with genomic data.
| Case 3 | Capacity Building in Genomics in
Developing Countries
The relative affordability of genomic analyses, once
data has been generated, may mean that this
research methodology lends itself well for successful
capacity building. A key aim of sustainable GWAS
ought to be that all researchers are able to analyse
and publish analyses of their data. However, in order
to ensure that all research sites are capable of
conducting site-specific analyses, the following need
to be considered:
Central Data Repository: Genomic data files are
large and require very significant computational
resources for confidential storage. For successful local
analyses, it may not be necessary to store the data at
all research sites; rather, a central data repository
may be a solution. A prerequisite, however, is that
such a repository can easily and securely be accessed
at a distance, and that tools exist that allow for rele-
vant data to be extracted and/or analysed when
necessary. It also requires a trusted body to maintain
and share the data.
Local Infrastructure: Ideally, investigators around
the world should be in a position to analyse genomic
data, and combine it where appropriate with clinical
data held locally. This would maximise the utility of
genomic data, provide career incentives, and possibly
generate new research findings that are specific for
the populations that donated samples. But such ana-
lyses will only take place if sufficient resources are
available locally to support them. Necessary for local
analyses are
￿ effective high-speed connectivity to the Internet;
￿ high speed computers;
￿ human resources including well-trained IT staff
and bioinformatics scientists;
￿ a supportive institutional environment that allows
staff to acquire the necessary skills, and that provides
career opportunities.
Network Infrastructure: Where research takes place
in international collaboration, then the network
should identify strengths and weaknesses for all part-
ner sites, and be committed to sharing these with
others. In particular, the network should seek to sup-
port local analyses, for instance by making a data
analyst available to all sites. Also, regular meeting
opportunities to discuss particular challenges, as well
as a mentoring scheme to support junior researchers
may be considered.
In the context of MalariaGEN, this challenge was
addressed in a training programme in which junior
researchers from the participating research centres
received intensive training in the analysis of genomic
data [15]. They participated in several data analysis
workshops and were also invited to the annual Malaria-
GEN meetings where they presented site-specific ana-
lyses. In addition, they received support to develop and
submit conference abstracts, and a sub-group also
received support to apply for PhD fellowships.
While this capacity building programme was success-
ful in engaging young local researchers in genomic
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long-term investment and commitment from all parties
in research. On the contrary, research projects often
have to rely on short-term research funding and have
milestones that need to be met. Also, it can only be
expected to be successful if linked into a supportive and
stable institutional environment. To train a group of
enthusiastic and young people in the scope of a few
years to a standard where they can successfully analyse
genomic data is then a significant challenge.
Second, although software can be developed which
allows researchers to conduct analyses at a distance, it
inevitably requires stable Internet connections. Although
the majority of research centres around the world now
have fairly stable access to the Internet, some centres
remain unconnected. In the context of an international
collaborative research project it is unfeasible to develop
computational and networking capacity at all the
research sites, which means that some sites may remain
at a disadvantage in terms of data utilization and analy-
sis. Site visits and local exchange of facilities may be a
solution to this problem.
Summary
The application of GWA methodology to poverty-
related diseases presents a wide range of ethical chal-
lenges. As our experiences with MalariaGEN have
shown, the three key challenges highlighted in the litera-
ture to date - namely consent, privacy and data release -
are by no means an exhaustive list. The ethical issues
relevant to GWA studies conducted on populations with
lower average income and literacy levels also include
issues around the inclusion and reuse of archived sam-
ples, export of samples, ethical review and capacity
building. We believe that identifying and addressing
ethical considerations should be integral to the develop-
ment of responsible whole-genome studies in recogni-
tion of the need to develop appropriate responses to
issues that are relevant to populations in low-income
countries.
The fact that collaborative genomics research in lower
income countries involves the establishment of large
and diverse scientific networks bringing together diverse
and interdependent forms of expertise and institutions
in higher and lower income countries, means that
responsibility for the ethical dimensions of such research
is inevitably shared. Important issues such as ownership
of samples and data and capacity to analyse genomic
data need to be addressed for such studies to be suc-
cessful. In addition to establishing means of developing
consensus about ethical issues to be addressed in their
research, networks need to determine how best to tailor
the implementation of ethical principles to individual
research sites.
In this paper, we have described the experiences of
exploring and addressing the ethical issues that emerged
in the context of the research of the MalariaGEN Net-
work. But one size does not fit all and the development
of appropriate responses to these ethical issues will need
to be conducted on a case by case basis. What will link
international genomics research projects, though, are
the more general principles of justice, ownership and
the fair distribution of resources. Given the urgent need
to alleviate the disease burden for people living in lower
income countries, and the tremendous opportunity to
redress wider issues of global injustice and inequality,
the need to tackle and resolve the ethical challenges sur-
rounding GWA studies is as important as it is acute.
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